• Quibim

  Participated · Equity · Dec 2016

  Quibim is a Valencia-based startup developing foundational AI models for medical imaging across oncology, immunology, neurology, and metabolic disorders. Its flagship product, QP-Prostate, is designed to improve prostate cancer detection from X-rays, CT scans, and MRIs, and the company is developing separate products for the brain, liver, breast, and lung. Quibim also offers QP-Insights for processing multi-omics data, intended for use in clinical trials and related studies. The company has FDA 510(k) clearance for QP-Prostate (2023), about 170 installations globally, and partnerships that include Stanford University and Mass General Brigham. Quibim has raised around $70 million since inception and plans to use new funding to accelerate product development and U.S. expansion. Longer-term, the company intends to create digital twins of the human body to serve dynamic models that improve diagnostic accuracy and disease understanding. QUIBIM develops QUIBIM Precision, an AI-powered radiology platform that extracts and quantifies disease-specific biomarkers from medical images to support diagnostics. The company has launched more than 20 algorithms covering conditions including cancer, Alzheimer’s, osteoarthritis and liver disease. Its products are used in over 70 hospitals and in 11 clinical trials worldwide. QUIBIM has been expanding into chest X-ray and CT scan algorithms for detecting COVID-19. The founders spun the company out of La Fe Health Research Institute in Valencia; the team’s imaging process was adopted as an industry standard by the European Society of Radiology in 2013. Following a recent capital injection, the company plans to promote new prostate, musculoskeletal and oncology solutions, expand its workforce and grow international sales and market presence. Quibim extracts quantitative imaging biomarkers from radiological and nuclear medicine images using original computational processing methods. Its core product is the Quibim Precision® cloud-based medical-imaging analysis platform, which can be deployed in private instances for hospitals and pharmaceutical companies running clinical trials. The platform processes X‑ray, ultrasound, CT, MRI and PET images with advanced algorithms including GPU processing, machine learning and big data methodologies. Quibim’s software aims to enrich diagnostic information and enable earlier assessment of pharmacological treatment response. The company is led by CEO Ángel Alberich-Bayarri and Dr. Luis Martí Bonmatí, who serves as director of the company’s Scientific Council and is a noted radiologist and director of the Clinical Imaging Area at Hospital Universitario y Politécnico La Fe. At the time of the report the team comprised 11 people; the company had previously closed a round in late 2016 and recently benefited from H2020 SME Instrument Phase II funding. Quibim (Quantitative Imaging Biomarkers in Medicine) is a medical‑imaging spin‑off from Instituto de Investigación Sanitaria La Fe, founded in 2012 and based in Valencia. The company offers a cloud analysis platform that processes radiological images and measures biomarkers of organs and tissues to enable earlier, more precise diagnoses and to evaluate early response to pharmacological treatments. The funds raised are intended to accelerate development and commercialization of that software. Quibim was founded by Ángel Alberich‑Bayarri and Dr. Luis Martí Bonmatí. The company was the first Spanish firm to receive financing from a technology‑transfer fund created within a public university.

• LetMeSpace

  Participated · Equity · Feb 2016

  LetMeSpace is a Barcelona-based portal that facilitates peer-to-peer rental of storage spaces between individuals. Founded in 2014 by Christian Picard and Etienne Darbousset, the company manages about 40,000 m2 of available space in Spain. It expected to reach 100,000 m2 within the year and to grow to roughly 2,000 hosts and 500 tenants. The startup operates in the internet/software sector and has allocated newly raised funds to develop mobile applications for Android and iOS. The product focus is on expanding marketplace supply and user base across Spain.

No current team members are available.